Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
2.
Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.
3.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
4.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
5.
The FDA Approves the New Frontline Aggressive ALL Regimen.
1.
The Science Behind Imatinib: How It Targets Cancer Cells
2.
Understanding Histiocytosis: Symptoms, Causes, and Treatment Options
3.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
4.
Case Study: Artificial Intelligence in Early Cancer Detection
5.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge